(NASDAQ: ROIV) Roivant Sciences's forecast annual revenue growth rate of 470.62% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 30.48%, and it is also forecast to beat the US market's average forecast revenue growth rate of 14.03%.
Roivant Sciences's revenue in 2026 is $7,532,000.On average, 14 Wall Street analysts forecast ROIV's revenue for 2027 to be $37,773,882,069, with the lowest ROIV revenue forecast at $9,843,818,048, and the highest ROIV revenue forecast at $70,011,880,552. On average, 13 Wall Street analysts forecast ROIV's revenue for 2028 to be $283,923,507,506, with the lowest ROIV revenue forecast at $84,237,310,009, and the highest ROIV revenue forecast at $483,320,775,797.
In 2029, ROIV is forecast to generate $1,126,101,580,385 in revenue, with the lowest revenue forecast at $723,767,661,030 and the highest revenue forecast at $1,656,286,673,395.